Lp-PLA2

Lp-PLA2

Abbreviation for lipoprotein-associated phospholipase 2.
References in periodicals archive ?
Lipoprotein-associated phosphohpase [A.sub.2] (Lp-PLA2), a member of the phospholipase superfamily, is an enzyme produced by monocytes and macrophages, T cells, and mast cells.
Klinik calisma acamasma gelmis olan terapotik girisimlerden biri lipoproteiniliskili fosfolipaz A2 (Lp-PLA2) inhibitoru olan darapladib ile yangisal yanitin ve plak biyolojisinin degistirilmeye calisilmasidir.
The researchers have revealed that the two biomarkers are lipoprotein-associated phospholipase A2 (Lp-PLA2) and high-sensitivity C-reactive protein (hs-CRP), which are known to be linked with the kind of stroke that occurs when blood flow to the brain is blocked.
Audioconference now available on CD ROM: "Lipoprotein-associated phospholipase A2 (Lp-PLA2): Biomarker of Inflammation," presented June 18, with Drs.
The PLAC[R] test measures blood levels of an enzyme called lipoprotein phospholipase A2 (Lp-PLA2).
Darapladib, which Glaxo discovered with Human Genome Sciences Inc.'s (Rockville MD) technology, is the first to inhibit an enzyme known as Lp-PLA2 that is associated with the buildup of plaque on the walls of arteries.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker reflecting a proinflammatory state.
diaDexus (Santa Clara, CA; 408-496-6600) announced the issuance of a United States patent covering a method for the diagnosis of a patient's susceptibility to atherosclerosis using antibodies against Lp-PLA2, a novel risk factor for coronary heart disease.
This includes leukocyte count, (47) markers of leukocyte activation such as myeloperoxidase (48), cytokines such as interleukin-6 (49), adhesion molecules such as soluble intercellular adhesion molecule 1 (sICAM-1) and P-selectin (50), and markers associated with lipid oxidation such as lipoprotein-associated phospholipase A2 (Lp-PLA2) (51) and pregnancy-associated plasma protein (PAPP) A (52).
A combination of LA and its metabolite GLA works synergistically in the cell membrane to reduce blood glucose and fortify the cellular fatty acids removed by elevated Lp-PLA2 in diabetics.
M2 PHARMA-July 17, 2014-FDA accepts diaDexus' 510(k) filing for PLAC Test for Lp-PLA2 Activity
M2 EQUITYBITES-October 16, 2013-diaDexus Inc reports launch of clinical programme to support the submission of its PLAC Test for Lp-PLA2 Activity(C)2013 M2 COMMUNICATIONS http://www.m2.com